- $9.19m
- $6.13m
- $5.42m
- 45
- 38
- 71
- 50
Annual cashflow statement for Biomerica, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
2020 May 31st | 2021 May 31st | R2022 May 31st | 2023 May 31st | 2024 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.34 | -6.47 | -4.53 | -7.14 | -5.98 |
| Depreciation | |||||
| Non-Cash Items | 0.216 | 2.69 | -0.143 | 1.35 | 0.622 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.57 | -1.85 | 3.6 | -0.038 | -0.379 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -4.3 | -5.25 | -0.479 | -5.47 | -5.36 |
| Capital Expenditures | -0.119 | -0.296 | -0.17 | -0.078 | -0.115 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | -0.119 | -0.296 | -0.17 | -0.078 | -0.115 |
| Financing Cash Flow Items | — | — | -0.085 | -0.705 | -0.081 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 12.4 | 1.11 | 2.39 | 9.39 | -0.081 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.95 | -4.44 | 1.72 | 3.8 | -5.55 |